These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25957957)

  • 41. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.
    Jacobs BA; Deenen MJ; Pluim D; van Hasselt JG; Krähenbühl MD; van Geel RM; de Vries N; Rosing H; Meulendijks D; Burylo AM; Cats A; Beijnen JH; Huitema AD; Schellens JH
    Br J Clin Pharmacol; 2016 Sep; 82(3):706-16. PubMed ID: 27161955
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
    Fleming RA; Milano G; Thyss A; Etienne MC; Renée N; Schneider M; Demard F
    Cancer Res; 1992 May; 52(10):2899-902. PubMed ID: 1581906
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.
    Ciccolini J; Mercier C; Dahan L; Evrard A; Boyer JC; Richard K; Dales JP; Durand A; Milano G; Seitz JF; Lacarelle B
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):272-5. PubMed ID: 16292536
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
    Peng RJ; Dong QM; Shi YX; Cao Y; Zhou ZM; Yuan ZY; Li S; Li H; Jiang WQ
    Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
    Moreno-Solórzano I; Ibeas-Rollan R; Monzó-Planella M; Moreno-Solórzano J; Martínez-Ródenas F; Pou-Sanchis E; Hernández-Borlan R; Navarro-Vigo M; Ortigosa-Rodríguez S; Gel-Moreno B
    Clin Colorectal Cancer; 2007 Sep; 6(9):634-40. PubMed ID: 17945035
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer.
    Ho DH; Covington W; Brown N; Lin SN; Pazdur R; Huo YY; Creaven PJ; Rustum YM; Meropol NJ; Lassere Y; Kuritani J; Hayakawa T
    Cancer Chemother Pharmacol; 2000; 46(5):351-6. PubMed ID: 11127938
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
    Salgado J; Zabalegui N; Gil C; Monreal I; Rodríguez J; García-Foncillas J
    Oncol Rep; 2007 Feb; 17(2):325-8. PubMed ID: 17203168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
    Thomas F; Hennebelle I; Delmas C; Lochon I; Dhelens C; Garnier Tixidre C; Bonadona A; Penel N; Goncalves A; Delord JP; Toulas C; Chatelut E
    Clin Pharmacol Ther; 2016 Feb; 99(2):235-42. PubMed ID: 26265035
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
    Saif MW; Diasio R
    Clin Colorectal Cancer; 2006 Jan; 5(5):359-62. PubMed ID: 16512996
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A case in which dihydropyrimidine dehydrogenase deficiency was strongly suspected during adjuvant chemotherapy with capecitabine for colon cancer].
    Toshima T; Kodera M; Yamashita Y; Oishi M; Seshimo K; Yamamura M; Kato H; Ikeda H; Mizuno K
    Gan To Kagaku Ryoho; 2013 Nov; 40(11):1549-52. PubMed ID: 24231713
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene.
    Kuilenburg ABPV; Meijer J; Tanck MWT; Dobritzsch D; Zoetekouw L; Dekkers LL; Roelofsen J; Meinsma R; Wymenga M; Kulik W; Büchel B; Hennekam RCM; Largiadèr CR
    Biochim Biophys Acta; 2016 Apr; 1862(4):754-762. PubMed ID: 26804652
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
    Baker SD; Khor SP; Adjei AA; Doucette M; Spector T; Donehower RC; Grochow LB; Sartorius SE; Noe DA; Hohneker JA; Rowinsky EK
    J Clin Oncol; 1996 Dec; 14(12):3085-96. PubMed ID: 8955653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.
    Sistonen J; Büchel B; Froehlich TK; Kummer D; Fontana S; Joerger M; van Kuilenburg AB; Largiadèr CR
    Pharmacogenomics; 2014 Sep; 15(13):1653-66. PubMed ID: 25410891
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer.
    Marin C; Krache A; Palmaro C; Lucas M; Hilaire V; Ugdonne R; De Victor B; Quaranta S; Solas C; Lacarelle B; Ciccolini J
    Clin Transl Sci; 2020 Jul; 13(4):761-768. PubMed ID: 32058656
    [TBL] [Abstract][Full Text] [Related]  

  • 55. D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer.
    Inanc M; Er O; Karaca H; Berk V; Ozkan M; Dikilitas M; Elmali F
    J BUON; 2013; 18(2):391-7. PubMed ID: 23818351
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantification of uracil, dihydrouracil, thymine and dihydrothymine for reliable dihydropyrimidine dehydrogenase (DPD) phenotyping critically depend on blood and plasma storage conditions.
    van den Wildenberg SAH; Streng AS; van den Broek R; Broeren MAC; Deenen MJ; van Dongen JLJ; Hanrath MA; Lapré C; Brunsveld L; Scharnhorst V; van de Kerkhof D
    J Pharm Biomed Anal; 2022 Nov; 221():115027. PubMed ID: 36099723
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
    Yamada Y
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
    Carrato A; Gallego-Plazas J; Guillén-Ponce C
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
    Ichikawa W; Uetake H; Shirota Y; Yamada H; Nishi N; Nihei Z; Sugihara K; Hirayama R
    Clin Cancer Res; 2003 Feb; 9(2):786-91. PubMed ID: 12576451
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
    Etienne-Grimaldi MC; Cardot JM; François E; Renée N; Douillard JY; Gamelin E; Milano G
    Clin Pharmacol Ther; 2008 Mar; 83(3):413-5. PubMed ID: 17637782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.